AR and prostate carcinoma: From the groundbreaking studies of Huggins and Hodges (Huggins and Hodges, 1972) to the development of novel, second-generation androgen receptor inhibitors (Scher et al., 2012; Beer et al., 2014; Smith et al., 2018; Chi et al., 2019; Fizazi et al., 2019; Armstrong et al., 2022), and anti-androgens (Fizazi et al., 2017; James et al., 2017), much of the existing treatment options for prostate cancer are currently focused on targeting the androgen receptor (AR) signaling axis.